14a Behandlung allg./ treatment » Rekonvaleszentenplasma/ convalescent plasma

Letzte Änderung: 06.12.2022 um 16:23 Uhr

"High-titer CCP may have benefited hospitalized patients with COVID-19 early in the pandemic when other treatments were not in use, suggesting a heterogenous treatment effect over time..."

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2787090


"Early administration of high titer SARS-CoV-2 convalescent plasma reduced outpatient hospitalizations by more than 50%. High titer convalescent plasma is an effective early outpatient COVID-19 treatment with the advantages of low cost, wide availability, and rapid resilience to variant emergence from viral genetic drift in the face of a changing pandemic."

https://www.medrxiv.org/content/10.1101/2021.12.10.21267485v1


Vor einer Gabe an erkrankte Patienten sollte ausgeschlossen werden, dass der Plasmaspender Antikörper gegen Interferon hatte. 




Weiterführende Links zum Artikel

Mehr zum Thema "14a Behandlung allg./ treatment"

Weitere Themen

« Zurück zur Übersicht